#特殊劑型：不建議磨粉、管灌藥品

For the treatment of the Parkinson’s disease

Ropinirole is a non-ergoline dopamine subtype selective agonist, and exerts activity in the CNS at D ₂ and D ₃ receptors, but have no activity at the D₁ receptor.

Bioavailability: 55% because of firs-pass metabolism; protein binding 10 to 40%; extensively metabolized in liver via CYP1A2 to inactive metabolites; elimination half-life: 6 hours.

Hypersensitivity to ropinirole or to any of the excipients

C

Avoided.

Common: nausea, vomiting, dizziness, fatigue, headache; Serious: orthostatic hypotension, syncope, dyskinesia, sleep attack, somnolence, hallucinations.

Parkinson's disease, Early disease: (extended-release) may switch directly from immediate-release ropinirole; start an extended-release dose that matches most closely with the total daily immediate-release dose, orally once daily. MAX dose 24 mg/day. Swallow tablet whole and do not chew, crush or divide.